Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2026-05-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - LATEST PIVOTAL STUDY RESULTS OF ASANDEUTERTINIB AS FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER WITH BRAIN METASTASES PRESENTED AS LBA AT 2026 ASCO ANNUAL MEET
Regulatory Filings Classification · 86% confidence The document is a voluntary announcement by TYK Medicines disclosing clinical study results for asandeutertinib. It is not an earnings release (no financial performance metrics in a financial reporting context), not a management or board change, not a proxy or dividend notice, nor a formal annual/interim report. It does not certify or attach a financial report, so it is not a report publication announcement. It falls into miscellaneous regulatory announcements under Hong Kong Listing Rules, making it a general Regulatory Filing (RNS).
2026-05-31 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING OF 2025 TO BE HELD ON TUESDAY, JUNE 23, 2026 AND ANY ADJOURNMENT THEREOF
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a form of proxy for the Annual General Meeting requiring shareholders to appoint proxies and vote on resolutions. It is distributed ahead of the meeting to solicit votes and provide meeting information. It is not the AGM materials themselves, nor the voting results, nor a full report, but a proxy solicitation document. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-05-22 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
AGM Information Classification · 85% confidence The document is the formal notice of the company’s 2025 Annual General Meeting, listing the date, venue, resolutions to be considered, proxy arrangements, and related meeting logistics. It is not a financial or operational report, an earnings release, or voting results, but rather the notice convening the AGM. This aligns with the "AGM Information" category.
2026-05-22 English
CIRCULAR OF 2025 AGM
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a shareholder circular containing the notice of the Annual General Meeting, explanatory information on resolutions (annual report approval, audited financial statements, director re-election, share mandates, amendments to articles of association, etc.), and proxy instructions. It is not the actual annual report or audited statements, but a solicitation for votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-22 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in share capital, issued shares, treasury shares, and public float sufficiency confirmation. It is a regulatory compliance report related to share capital and public float requirements under the Exchange Listing Rules. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of a report publication but a regulatory filing itself. The document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-05-06 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' for TYK Medicines, Inc. It contains detailed sections typical of an annual report, including Corporate Information, Chairman's Statement, Financial Highlights, Business Highlights, Directors and Senior Management, Directors' Report, Corporate Governance Report, Environmental, Social and Governance Report, Independent Auditor's Report, and detailed financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, and Notes to Financial Statements. The length of the document is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content includes comprehensive financial data, management discussion, and analysis, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.